Standout Papers

Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myelo... 2000 2026 2008 2017 3.7k
  1. Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia (2001)
    Brian Druker, Moshe Talpaz et al. New England Journal of Medicine
  2. Abl Protein-Tyrosine Kinase Inhibitor STI571 Inhibits In Vitro Signal Transduction Mediated by c-Kit and Platelet-Derived Growth Factor Receptors (2000)
    Elisabeth Buchdunger, Catherine L. Cioffi et al. Journal of Pharmacology and Experimental Therapeutics

Immediate Impact

5 by Nobel laureates 23 from Science/Nature 200 standout
Sub-graph 1 of 17

Citing Papers

Small molecules, big impact: 20 years of targeted therapy in oncology
2020 Standout
Challenges and Opportunities in Cancer Drug Resistance
2020 Standout
29 intermediate papers

Works of Sayuri Ohno-Jones being referenced

Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia
2001 Standout
Abl Protein-Tyrosine Kinase Inhibitor STI571 Inhibits In Vitro Signal Transduction Mediated by c-Kit and Platelet-Derived Growth Factor Receptors
2000 Standout
and 5 more

Author Peers

Author Last Decade Papers Cites
Sayuri Ohno-Jones 3712 2453 1822 7 6.1k
Debra Resta 6034 4335 3080 22 8.8k
Shu Tamura 2508 1591 1120 12 3.7k
J. Zimmermann 3260 2067 1456 47 6.1k
Gerald M. Segal 2497 1350 839 20 3.8k
Nicholas Lydon 7106 4730 3271 39 12.4k
Renaud Capdeville 6628 4895 3245 49 12.7k
Stephen G. O’Brien 3709 3058 2017 43 4.4k
Neil P. Shah 7097 5660 3808 49 8.6k
Susan O’Brien 4258 3395 1909 73 5.7k
Diana Griffith 1124 600 659 22 5.0k

All Works

Loading papers...

Rankless by CCL
2026